Ignite Creation Date:
2025-12-24 @ 9:35 PM
Ignite Modification Date:
2026-01-01 @ 6:50 PM
Study NCT ID:
NCT03094832
Status:
TERMINATED
Last Update Posted:
2023-04-13
First Post:
2017-03-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module